T cells expressing chimeric antigen receptors (CAR-T) are one of the major breakthroughs in the field of cancer treatment in recent years, and they have achieved excellent efficacy in the treatment ofRead More…
As a precision targeted therapy for tumor treatment, CAR-T (chimeric antigen receptor t-cell immunotherapy) has achieved promising results in clinical tumor treatment with optimization and improvement in recent years. It is cutting-edgeRead More…
At present, the vaccine research for the Coronavirus Disease (COVID-19) is in progress, but the drug research and development for severe COVID-19 remains a thorny scientific problem. Up to now, there isRead More…
On July 9th, Fate Therapeutics announced that U.S. Food and Drug Administration has approved the first IND application for iPSC-derived allogeneic CAR-T cell therapy FT819 for the treatment of recurrent/refractory B-cell malignant tumors,Read More…
Ten years ago, scientists announced the development of cancer immunotherapy called chimeric antigen receptor-T cell (CAR-T) therapy: genetically modifying T cells from patients to make them powerful anti-tumor effects, and then infusingRead More…
Recently, it was announced that LineaRx (a part of Applied DNA Science), a company specializing in next-generation biotherapy, has achieved anti-CD19-CAR (chimeric antigen receptor) expression on human T cells through its proprietaryRead More…
More and more cancer patients are receiving a promising new treatment called CAR-T cell therapy. In this treatment, the patient’s own T cells are removed from the body and genetically modified toRead More…
Scientists have been hugely successful in developing a new type of anti-cancer therapy, immunotherapy, over the past decade, a treatment that attacks cancer cells by activating the body’s autoimmune system. One of theRead More…
Scientists at Stanford University developed a new CAR-T therapy that can eradicate many types of childhood tumors in a mouse study, which was published in Clinical Cancer Research on January 17, furtherRead More…
The unique advantages of CAR-T therapy in the treatment of hematological tumors have once again become a hot spot for the recent American Society of Hematology (ASH) Annual Meeting, and bispecific antibodiesRead More…